Research Article | Open Access
Mitochondria-Targeted Peptide SS31 Attenuates Renal Tubulointerstitial Injury via Inhibiting Mitochondrial Fission in Diabetic Mice
Objective. Renal tubular injury is an early characteristic of diabetic nephropathy (DN) that is related to mitochondrial dysfunction. In this study, we explore the effects and mechanisms of mitochondria-targeted peptide SS31 on renal tubulointerstitial injury in DN. Method. 40 C57BL/6 mice were randomly divided into control group, STZ group, STZ+SS31 group, and STZ+normal saline group. SS31 was intraperitoneally injected to the mice every other day for 24 weeks. Renal lesions and the expression of Drp1, Mfn1, Bcl-2, Bax, Caspase1, IL-1β, and FN were detected. In in vitro studies, HK-2 cells were incubated with different concentrations of D-glucose (5, 30 mM) or combined with SS31 and Drp1 inhibitor Midivi1. Mitochondrial ROS, membrane potential, and morphology have been detected to evaluate the mitochondrial function. Results. Compared with diabetic mice, the levels of serum creatinine and microalbuminuria were significantly decreased in the SS31 group. Renal tubulointerstitial fibrosis, oxidative stress, and apoptosis were observed in diabetic mice, while the pathological changes were reduced in the SS31-treatment group. SS31 could decrease the expression of Drp1, Bax, Caspase1, IL-1β, and FN in the renal tissue of diabetic mice, while increasing the expression of Mfn1. Additionally, mitochondria exhibit focal enlargement and crista swelling in renal tubular cells of diabetic mice, while SS31 treatment could partially block these changes. An in vitro study showed that pretreatment with SS31 or Drp1 inhibitor Mdivi1 could restore the level of mitochondrial ROS, the membrane potential levels, and the expressions of Drp1, Bax, Caspase1, IL-1β, and FN in HK-2 cells under high-glucose conditions. Conclusion. SS31 protected renal tubulointerstitial injury in diabetic mice through a decrease in mitochondrial fragmentation via suppressing the expression of Drp1 and increasing the expression of Mfn1.
Diabetic nephropathy (DN) is a severe complication of diabetic patients [1, 2]; it not only decreases the quality of life in DN patients but also brings serious economic burden on society. Unfortunately, the pathogenesis of DN is still not fully understood. Conventional wisdom suggested that glomerular lesions played the major roles in the progression of DN, while tubulointerstitial injury was regarded as a secondary lesion. But recent studies have shown that tubulointerstitial injury could serve as a primary pivotal site for the development of DN [3, 4]. As renal tubular reabsorption required a large amount of adenosine triphosphate (ATP) from mitochondria, it indicated that normal mitochondrial function was of greatest importance for maintaining a good functionality kidney. The application of mitochondrial dysfunction in DN tubulointerstitial damage is now receiving more and more recognition , and potential new pharmacological therapy that targeted on mitochondria may be effective in fighting DN.
Recently, a novel antioxidative peptide targeted on mitochondria named MTP131 or SS31 was designed . SS31 peptide (H-D-Arg-Dmt-Lys-Phe-NH2) could specially concentrate in the inner mitochondrial membrane. It has been demonstrated that SS31 has excellent therapeutic efficacy in myocardial injury, neurodegeneration injury, and diabetic complications [7–10]. Our previous study demonstrated that mitochondria-targeted peptides (MTP131 and SPI20) could prevent contrast-induced acute kidney injury in rats . In addition, in vitro experiments showed that SS31 could attenuate hypoxia-induced renal tubular epithelial cell apoptosis . Furthermore, Hou et al. found that SS31 attenuated renal injury via decreasing mitochondrial ROS in diabetic mice . However, the protective effect of these peptides on diabetes-induced renal tubulointerstitial injury was incompletely understood. Therefore, we performed this study to explore the effects and mechanisms of SS31 on DN both in vivo and in vitro.
2. Research Design and Methods
2.1. Cell Lines and Reagents
Human proximal tubular epithelial cells (HK-2 cells) were cryopreserved at the Institute of Kidney Disease, Central South University. SS31 was synthesised and provided by Chinapeptide Co. Ltd. (Shanghai, China). Streptozocin (STZ) was obtained from Sigma-Aldrich (USA). The selective Drp1 inhibitor Mdivi1 (ab144589) was obtained from Abcam (UK). Anti-fibronectin (FN) antibody (sc-52331), anti-Bcl-2 antibody (sc-56015), anti-IL-1β antibody (sc-52012), and anti-Bax antibody (sc-20067) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Drp1 rabbit monoclonal antibody (ab184247), anti-Mfn1 mice monoclonal antibody (ab57602), and Caspase1 antibody (ab138483) were purchased from Abcam (UK). The TUNEL assay kit (ab66110) and anti-β-actin antibody (ab8226) were purchased from Abcam (UK). Secondary antibodies in this study were purchased from KangChen Bio-tech (Shanghai, China). Other materials, including bovine serum albumin and low-glucose DMEM medium, were purchased from Gibco (USA).
2.2. Animal Experimental Design
A total of 40 eight-week-old C57BL/6 mice (about 20 g body weight) were purchased from Slyke Jingda Biotechnology Company (Hunan, China), then they were divided into 4 groups. The control group was injected with sodium citrate buffer only (). The second group was injected intraperitoneally with STZ (40 mg/kg body weight) for 5 consecutive days (n = 10), and mice with glucose were considered a diabetic model. If the level of blood glucose did not meet the standard, the mice had to resume taking injection of STZ until reaching blood glucose . The third group of STZ-induced diabetic mice was injected with normal saline (NS) (5 ml/kg) (). The fourth group of diabetic mice was intraperitoneally injected with SS31 (3 mg/kg body weight) every other day for 24 weeks. They were killed at 24 weeks following the onset of STZ-induced diabetes. The sera and kidneys were harvested for further detection. The animal experiments were approved by the Ethics Review Committee of the Third Xiangya Hospital, Central South University.
2.3. Morphological Studies
Renal tissue sections were cut for hematoxylin-eosin (H&E), periodic acid-Schiff (PAS), and Masson's staining as described previously; glomerular and tubular injury was analyzed using a semiquantitative scoring system as previously described .
2.4. Assessment of Biochemical Index
Blood glucose was tested using a blood glucose monitor (Roche Accu-Chek, Germany) every two weeks. Mice were placed in individual metabolic cages for a 24-hour urine collection. A mouse urine albumin ELISA kit (Bethyl Laboratories, USA) was used to measure urine albumin concentrations. Serum creatinine, triglyceride, and cholesterol levels were measured by an automated biochemical analyzer (Hitachi 7600, Japan).
2.5. Renal Tissue Immunohistochemistry (IHC) and Apoptosis Assessment
Mouse renal tissue sections (3 μm thick) was prepared; after deparaffinization, rehydration, and antigen retrieval, the sections were incubated with various primary antibodies FN (1: 100 dilution), Bcl-2 (1:100 dilution), Bax (1:100 dilution), IL-1β (1:100 dilution), Caspase1 (1:100 dilution), Mfn1 (1:100 dilution), and Drp1 (1:100 dilution) and then incubated with secondary antibodies; the sections were finally prepared for DAB reaction. Renal cell apoptosis assessment was performed using TUNEL staining as previously described .
2.6. Cell Culture and Treatment
HK-2 cells were maintained in media containing 5-30 mM D-glucose and other interventions: HK-2 cells maintained in 5 mM D-glucose (LG), HK-2 cells maintained in 30 mM D-glucose (HG), HK-2 cells treated with HG plus SS31 (100 nM), HK-2 cells treated with HG plus Mdivi1 (50 μM), and HK-2 cells maintained in HG medium and normal saline. HK-2 cells treated with various agents were incubated for the indicated time (72 h).
2.7. Western Blotting Studies
Briefly, after the fractionated proteins were transferred onto a nitrocellulose membrane, they were incubated with various primary antibodies anti-FN (1:1,000), anti-Bcl-2 (1:1,000), anti-Bax (1:1,000), anti-IL-1β (1:1000), anti-Caspase1 (1:1,000), anti-Mfn1 (1:1,000), anti-Drp1 (1:1,000), and anti-β-actin (1:1,000); the membranes were then immersed in solutions containing secondary antibodies. The ECL system (Amersham, USA) was used for autoradiograms .
2.8. Cell Immunofluorescence
After HK-2 cells were treated with various agents, the cells were first immersed in MitoTracker Red (1:1000) solution, then the cells were fixed and permeabilized. After that, the cells were incubated with primary antibody (Drp1, 1:100 dilution). The cells were then incubated with FITC-conjugated secondary antibody and DAPI, and finally a confocal laser scanning microscope was used to capture images (Zeiss LSM 780).
2.9. Confocal Microscopy
A LSM 780 META laser scanning microscope (Zeiss LSM780) was used to complete the confocal microscopy examination. The LSM 510 software (Zeiss) was used for image analysis .
2.10. Examination of Mitochondrial Morphology Using Electron Microscopy
We used transmission electron microscopy (EM) to observe mitochondrial morphology. Briefly, renal cortices were minced into 1 mm3 pieces, then renal cortices were fixed with 2.5% glutaraldehyde; lastly, thin sections were prepared for EM to delineate the mitochondrial morphology in tubules.
2.11. Assessment of Mitochondrial ROS and Mitochondrial Membrane Voltage Potential (MMP, ΔΨm)
HK-2 cells were incubated with MitoSOX and examined by confocal microscopy to assess mitochondrial ROS levels. The cells were stained with TMRE and examined by confocal microscopy to evaluate the perturbations of MMP (ΔΨm). Mean fluorescence intensity was calculated based on 10 randomly selected fields.
2.12. Measurement of Oxidative and Antioxidative Biomarkers
MDA content as well as SOD and GSH-PX activities were determined by chemiluminescence methods as previously described .
2.13. Statistical Analysis
We used SPSS 16.0 software to analyze the experimental results. The results were expressed as deviation (SD). To assess for the results of between-group differences, analysis of variance with post hoc Tukey test was used. was considered statistically significant.
3.1. Effects of SS31 on Biochemical Parameters in Diabetic Mice
At the end of 24 weeks, 3 mice in the STZ group died, 3 mice in the STZ+SS31 group died, and 2 mice in the STZ+NS group died. Administration of SS31 for 24 weeks had no effect on body weight and blood glucose levels (Table 1, Figures 1(a) and 1(b)), while it decreased the level of proteinuria in STZ mice (Table 1, Figure 1(c)). Similarly, the levels of serum creatinine (Scr) and blood urea nitrogen (BUN) were increased in STZ mice, and SS31 treatment could restore these changes (Table 1). In addition, renal malondialdehyde (MDA) level was increased, while renal superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) levels were significantly decreased in diabetic mice; these changes were significantly reversed by SS31 treatment (Figures 1(d)–1(f)).
Note: BS: blood glucose; BW: body weight; KW: kidney weight of the right kidney; Scr: serum creatinine; BUN: blood urea nitrogen; TC: total cholesterol; TG: triglyceride. &3 mice in the STZ group died, 2 mice in the STZ+saline group died, and 3 mice in the STZ+SS31 group died during 24 weeks. , vs. control group; , vs. control group; , vs. STZ group; , vs. STZ group.
3.2. Effects of SS31 on Glomerular Injury and Tubulointerstitial Damage in Diabetic Mice
It showed that SS31 treatment significantly alleviated mesangial matrix proliferation compared with untreated diabetic mice as indicated by HE, PAS staining, and glomerular damage scores (Figures 2(a) and 2(c)). In addition, increased renal interstitial fibrosis and tubulointerstitial matrix deposition were observed in the kidney of STZ-induced diabetic mice at the end of 24 weeks (Figures 2(a) and 2(b)). Furthermore, the expression of FN was significantly increased in the renal tubular interstitial region of STZ induced diabetic mice (Figures 2(a), 2(d), and 2(e)), while SS31 administration could markedly decrease these tubulointerstitial lesions (Figures 2(a), 2(d), and 2(e)).
3.3. Effects of SS31 on Renal Apoptosis in Diabetic Mice
As shown in Figure 3, TUNEL-IHC staining showed that tubular epithelial cell apoptosis was observed in the kidney of STZ-induced diabetic mice, which was notably alleviated following SS31 treatment (Figures 3(a) and 3(b)). Furthermore, immunohistochemistry and Western blotting analysis showed that the expression of Bax in renal tissue from the STZ group was increased compared with that from the control group. Conversely, the expression of Bcl-2 was significantly decreased in the STZ group. SS31 treatment significantly increased the expression of Bcl-2 and decreased the expression of Bax protein in diabetic mice, respectively (Figures 3(a) and 3(c)–3(e)).
3.4. Effect of SS31 on the Expression of IL-1β, Caspase1, Mfn1, and Drp1 in Diabetic Kidneys
IHC staining showed that renal IL-1β, Caspase1, and Drp1 expression was notably increased in diabetic mice; conversely, the expression of Mfn1 was decreased in STZ mice (Figure 4(a)). In addition, we found that Drp1 and Mfn1 were mainly expressed in renal tubules; however, after SS31 treatment for 24 weeks, these changes were significantly reversed. To confirm the above results, Western blot analysis was performed; similar results were observed regarding IL-1β, Caspase1, Mfn1, and Drp1 protein expression (Figures 4(b)–4(f)).
3.5. SS31 Restored Mitochondrial Morphology and Mitigated Mitochondrial ROS Generation
As shown in Figure 5, electron microscopy (EM) observation showed that the tubular mitochondria exhibit deformations in diabetic mice, such as mitochondrial crista swelling and focal disruption of the inner mitochondrial membranes (Figure 5(a)); SS31 treatment could obviously reverse these changes (Figures 5(a) and 5(c)). In vitro studies showed that HK-2 cells under an HG environment reduced mitochondrial membrane potential (MMP) and increased mitochondrial ROS levels, as indicated by TMRE and MitoSOX Red staining, respectively (Figures 5(b), 5(d), and 5(e)), these changes were reversed in cells pretreated with SS31. Interestingly, pretreatment with Drp1 inhibitor Mdivi1 also decreased the level of mitochondrial ROS in HK-2 cells exposed to an HG environment (Figures 5(b), 5(d), and 5(e)), and the MMP level was restored in HK-2 cells exposed to HG condition pretreatment with Mdivi1 (Figures 5(b), 5(d), and 5(e)).
3.6. SS31 Downregulated Drp1, Caspase1, and IL-1β Expression in HK-2 Cells Exposed to HG Conditions
Immunofluorescence studies indicated that HG increased Drp1 expression; additionally, MitoTracker staining showed increased mitochondrial fragmentation in HK-2 cells exposed to HG conditions (Figure 6(a)). These effects were reversed by SS31 treatment. In addition, we also found that pretreatment with Mdivi1 could decrease Drp1 expression in HK-2 cells under HG concentration (Figure 6(a)), then we investigated the effects of SS31 on Drp1, Mfn1, Caspase1, and IL-1β protein expression using Western blot analysis; as shown in Figure 6(b), increased expression of Drp1, Caspase1, and IL-1β were found in HK-2 cells exposed to HG condition, while the expression of Mfn1 was decreased in HK-2 cells under HG ambience. In addition, Western blot analysis showed that SS31 or Mdivi1 treatment could decrease the expression of Drp1, Caspase1, and IL-1β induced by HG; conversely, SS31 treatment could increase the expression of Mfn1 (Figures 6(b)–6(f)).
The present study indicates that SS31 ameliorates renal tubulointerstitial injury in diabetic mice, which might be due to an antioxidant action, as well as decreasing mitochondrial fragmentation then restoration of mitochondria morphology via suppressing the expression of Drp1 and increasing the expression of Mfn1 in renal tubular epithelial cells.
The mitochondria target peptides included SS01, SS02, SS20, and SS31; the structural motif of these peptides was an alternation of aromatic residues and basic amino acids. It has been shown that SS31 could concentrate more than 1000-fold in the mitochondria . The structure of these peptides includes tyrosine-containing analogs; they could scavenge free radicals (e.g., H2O2 and ONOO-). It was reported that SS31 might be beneficial for diseases associated with oxidative stress [18–20]. In addition, in vitro studies also demonstrated that these peptides could significantly attenuate the mitochondrial permeability transition (MPTP), cytochrome-C release, and mitochondrial swelling . Our study found that long-term treatment with SS31 in diabetic mice could reduce renal oxidative stress levels, and more importantly, we found that SS31 treatment might alleviate renal tubulointerstitial injury induced by high glucose via regulating mitochondrial fragmentation for the first time.
Conventional wisdom suggested that glomerular injury was the major source of DN; however, recent studies indicated that tubulointerstitial lesions also closely correlated with the progression of DN, and the tubulointerstitial injury has been described as diabetic tubulopathy [16, 22, 23]. It has been found that renal tubular damage markers appeared before microalbuminuria; it indicated that tubular injury contributed to the primary renal injury in the pathogenesis of DN [24, 25]. In this study, notable changes including apoptosis and fibrosis in the tubulointerstitial were also observed in 24-week STZ-induced diabetic mice. The mechanisms of renal tubulointerstitial injury were not fully clear; previous research has shown that mitochondrial dysfunction played a crucial role in this process [15, 26]. This raised an interesting question of whether alleviation of mitochondrial dysfunction by exogenous therapeutic agents could delay the progression of DN. Our findings indicated that SS31, a mitochondrial ROS inhibitor, not only ameliorated morphological mitochondrial abnormalities but also reduced diabetic tubular injury.
The kidney is an organ needing continuous energy consumption due to the excretion and reabsorption process that existed in the renal tubule; there was a large amount of mitochondria both in the tubular and glomerular cells, particularly in the proximal tubular cells , and, notably, normal mitochondrial function was very critical for kidney cells. However, increasing in vivo and in vitro studies indicated that mitochondrial dysfunction played a critical biological role in the progression of various kidney diseases, including DN [5, 27], such as mitochondrial dynamic disorders and elevated mitochondrial oxidative stress. For instance, Yiu et al. found that the oxidative markers were significantly increased in the kidney of diabetic mouse, and reduced ROS generation could attenuate renal fibrosis . In line with these observations, this research also confirmed that excessive mitochondrial ROS in the renal tissue of STZ induced diabetic mice.
Mitochondria are a class of highly shape-changed organelles which constantly undergo fusion and fission. In physiological conditions, they were elongated and filamentous, but the shape changed to fragment under stress including various kidney diseases [29–31]. Some key factors including fission mediators (Fis1, Drp1, and Dnm1) and the fusion proteins (Mfn1, Mfn2, and OPA1) controlled the balance of mitochondrial fusion and fission to maintain mitochondrial homeostasis . This balance was disrupted under intracellular or extracellular stresses; mitochondria were changed from an elongated network into short rod spheres; this process is called mitochondrial fragmentation . It has been demonstrated that Drp1 is an important regulator of mitochondrial fragmentation in diabetic conditions . Importantly, excessive mitochondrial fission was related to increased mitochondrial ROS production and cellular apoptosis [34–36]. These previous findings suggested that Drp1 was a key regulatory factor for mitochondrial fragmentation in the renal cells of DN, and Drp1 might be a novel therapeutic target for DN. In this study, EM observation showed that the tubular mitochondria were swelled, shorter, and disrupted in 24-week diabetic mice, while treatment with SS31 could restore renal tubular mitochondria to be elongated structures. In order to explore the protection mechanisms of SS31, we found that SS31 treatment in STZ-induced diabetic mice could significantly attenuate renal oxidative stress and apoptosis and reduce the expression of the mitochondrial fission factor, Drp1, while the mitochondrial fusion protein (Mfn1) was increased after SS31 treatment. To confirm these findings, we performed an in vitro study using HK-2 cells. Increased expression of Drp1 and excessive mitochondrial ROS has been observed in the HK-2 cells exposed to high glucose, while these changes were reversed by SS31 treatment. Interestingly, similar results were noted in the group pretreatment with Mdivi1. It indicated that SS31 has a similar effect with Mdivi1 on inhibiting the expression of Drp1. In addition, in vitro studies showed that SS31 treatment could increase the expression of Mfn1. These findings indicated that SS31 mediated renal protection effects most likely via inhibiting Drp1 and activating Mfn1.
Because of a variety of reasons, there still existed several drawbacks in this study; first, we just examined the effects of SS31 on oxidative stress and apoptosis, while other effects such as anti-inflammatory effect had not been evaluated. Second, as we discussed above, mitochondrial fusion and fission were regulated by several factors (e.g., Drp1, Mfn1, OPA1, Mfn2, and Fis1), but in this study, we just examined the inhibiting effect of SS31 on Drp1 and the increasing effect of SS31 on Mfn1. Third, in the vitro experiment, we found that SS31 could inhibit the expression of Drp1 in HK-2 cells under HG condition, and the inhibiting effect was similar with Mdivi1; however, the results were suggestive and not cause-and-effect. In the future study, we will further investigate the more detailed molecular mechanism about SS31 regulating mitochondrial dynamics.
In conclusion, our data showed that SS31 could protect renal tubulointerstitial injury and reduce ROS and apoptosis in diabetic mice, which might be due to the decrease in mitochondrial fragmentation via suppressing the expression of Drp1 and increasing the expression of Mfn1.
The data used to support the findings of this study are available from the first author and corresponding author upon reasonable request.
Conflicts of Interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Shi-kun Yang, Ai-mei Li, and Ya-chun Han contributed equally to this work.
This study was supported by grants from the National Natural Science Foundation of China (81500558, 8197033544, 81870498, and 81600566), Natural Science Foundation of Hunan Province (2018JJ3785), the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (JY201521), and Zhejiang Natural Science Foundation (LQ16H050001).
- A. Martinez-Castelao, J. F. Navarro-Gonzalez, J. L. Gorriz, and F. de Alvaro, “The concept and the epidemiology of diabetic nephropathy have changed in recent years,” Journal of Clinical Medicine, vol. 4, no. 6, pp. 1207–1216, 2015.
- M. C. Thomas, M. E. Cooper, and P. Zimmet, “Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease,” Nature Reviews Nephrology, vol. 12, no. 2, pp. 73–81, 2016.
- T. Fiseha and Z. Tamir, “Urinary markers of tubular injury in early diabetic nephropathy,” International Journal of Nephrology, vol. 2016, Article ID 4647685, 10 pages, 2016.
- J. Slyne, C. Slattery, T. McMorrow, and M. P. Ryan, “New developments concerning the proximal tubule in diabetic nephropathy:in vitromodels and mechanisms,” Nephrology Dialysis Transplantation, vol. 30, Suppl 4, pp. iv60–iv67, 2015.
- S. Yang, Y. Han, J. Liu et al., “Mitochondria: a novel therapeutic target in diabetic nephropathy,” Current Medicinal Chemistry, vol. 24, no. 29, pp. 3185–3202, 2017.
- M. Rocha, A. Hernandez-Mijares, K. Garcia-Malpartida, C. Banuls, L. Bellod, and V. M. Victor, “Mitochondria-targeted antioxidant peptides,” Current Pharmaceutical Design, vol. 16, no. 28, pp. 3124–3131, 2010.
- F. Y. Lee, P. L. Shao, C. Wallace et al., “Combined therapy with SS31 and mitochondria mitigates myocardial ischemia-reperfusion injury in rats,” International Journal of Molecular Sciences, vol. 19, no. 9, p. 2782, 2018.
- M. J. Calkins, M. Manczak, and P. H. Reddy, “Mitochondria-targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease,” Pharmaceuticals, vol. 5, no. 10, pp. 1103–1119, 2012.
- I. Escribano-Lopez, N. Diaz-Morales, F. Iannantuoni et al., “The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes,” Scientific Reports, vol. 8, no. 1, p. 15862, 2018.
- X. Wang, D. Tang, Y. Zou et al., “A mitochondrial-targeted peptide ameliorated podocyte apoptosis through a HOCl-alb-enhanced and mitochondria-dependent signalling pathway in diabetic rats and in vitro,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 34, no. 1, pp. 394–404, 2019.
- S. B. Duan, S. K. Yang, Q. Y. Zhou et al., “Mitochondria-targeted peptides prevent on contrast-induced acute kidney injury in the rats with hypercholesterolemia,” Renal Failure, vol. 35, no. 8, pp. 1124–1129, 2013.
- W. Y. Zhao, S. Han, L. Zhang, Y. H. Zhu, L. M. Wang, and L. Zeng, “Mitochondria-targeted antioxidant peptide SS31 prevents hypoxia/reoxygenation-induced apoptosis by down-regulating p66Shc in renal tubular epithelial cells,” Cellular Physiology and Biochemistry, vol. 32, no. 3, pp. 591–600, 2013.
- Y. Hou, S. Li, M. Wu et al., “Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy,” American Journal of Physiology-Renal Physiology, vol. 310, no. 6, pp. F547–F559, 2016.
- M. Zhan, I. M. Usman, L. Sun, and Y. S. Kanwar, “Disruption of renal tubular mitochondrial quality control by Myo-inositol oxygenase in diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 26, no. 6, pp. 1304–1321, 2015.
- L. Xiao, X. Zhu, S. Yang et al., “Rap1 ameliorates renal tubular injury in diabetic nephropathy,” Diabetes, vol. 63, no. 4, pp. 1366–1380, 2014.
- S. Yang, L. Zhao, Y. Han et al., “Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc,” Redox Biology, vol. 13, pp. 482–497, 2017.
- Y. Han, X. Xu, C. Tang et al., “Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis,” Redox Biology, vol. 16, pp. 32–46, 2018.
- Y. Hou, Y. Shi, B. Han et al., “The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 33, no. 11, pp. 1908–1918, 2018.
- H. I. Lu, F. Y. Lee, C. G. Wallace et al., “SS31 therapy effectively protects the heart against transverse aortic constriction-induced hypertrophic cardiomyopathy damage,” American Journal of Translational Research, vol. 9, no. 12, pp. 5220–5237, 2017.
- W. Ma, X. Zhu, X. Ding et al., “Protective effects of SS31 on t-BHP induced oxidative damage in 661W cells,” Molecular Medicine Reports, vol. 12, no. 4, pp. 5026–5034, 2015.
- K. Zhao, G. M. Zhao, D. Wu et al., “Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury,” Journal of Biological Chemistry, vol. 279, no. 33, pp. 34682–34690, 2004.
- S. C. W. Tang and K. N. Lai, “The pathogenic role of the renal proximal tubular cell in diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3049–3056, 2012.
- Y. S. Kanwar, L. Sun, P. Xie, F. Y. Liu, and S. Chen, “A glimpse of various pathogenetic mechanisms of diabetic nephropathy,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, no. 1, pp. 395–423, 2011.
- J. A. M. de Carvalho, E. Tatsch, B. S. Hausen et al., “Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes,” Clinical Biochemistry, vol. 49, no. 3, pp. 232–236, 2016.
- S. C. W. Tang, J. C. K. Leung, and K. N. Lai, “Diabetic tubulopathy: an emerging entity,” Contributions to Nephrology, vol. 170, pp. 124–134, 2011.
- L. Xiao, X. Xu, F. Zhang et al., “The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1,” Redox Biology, vol. 11, pp. 297–311, 2017.
- P. Bhargava and R. G. Schnellmann, “Mitochondrial energetics in the kidney,” Nature Reviews Nephrology, vol. 13, no. 10, pp. 629–646, 2017.
- W. H. Yiu, D. W. L. Wong, H. J. Wu et al., “Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress,” Kidney International, vol. 89, no. 2, pp. 386–398, 2016.
- O. E. Aparicio-Trejo, E. Tapia, E. Molina-Jijón et al., “Curcumin prevents mitochondrial dynamics disturbances in early 5/6 nephrectomy: relation to oxidative stress and mitochondrial bioenergetics,” BioFactors, vol. 43, no. 2, pp. 293–310, 2017.
- M. Morigi, L. Perico, C. Rota et al., “Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury,” Journal of Clinical Investigation, vol. 125, no. 2, pp. 715–726, 2015.
- M. Zhan, C. Brooks, F. Liu, L. Sun, and Z. Dong, “Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology,” Kidney International, vol. 83, no. 4, pp. 568–581, 2013.
- M. Cherubini and S. Gines, “Mitochondrial fragmentation in neuronal degeneration: toward an understanding of HD striatal susceptibility,” Biochemical and Biophysical Research Communications, vol. 483, no. 4, pp. 1063–1068, 2017.
- W. Wang, Y. Wang, J. Long et al., “Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells,” Cell Metabolism, vol. 15, no. 2, pp. 186–200, 2012.
- A. S. Gonzalez, M. E. Elguero, P. Finocchietto et al., “Abnormal mitochondrial fusion-fission balance contributes to the progression of experimental sepsis,” Free Radical Research, vol. 48, no. 7, pp. 769–783, 2014.
- J. Y. Li, K. Zhang, D. Xu et al., “Mitochondrial fission is required for blue light-induced apoptosis and mitophagy in retinal neuronal R28 cells,” Frontiers in Molecular Neuroscience, vol. 11, p. 432, 2018.
- M. Zhan, I. Usman, J. Yu et al., “Perturbations in mitochondrial dynamics by p66Shc lead to renal tubular oxidative injury in human diabetic nephropathy,” Clinical Science, vol. 132, no. 12, pp. 1297–1314, 2018.
Copyright © 2019 Shi-kun Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.